Additional loans committed.
Additional Loans Committed
Additional Loans Committed
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Expected volatility, Maximum
Fair Value Assumptions Expected volatility Rate Maximum
Forecast [Member]
Forecast [Member]
Forecast[Member]
Annual License Fees
Annual License Fees
Increase (Decrease) in Operating Liabilities [Abstract]
Increase (decrease) in:
Restructuring Type [Axis]
Two thousand and twenty equity incentive plan [Member].
Two Thousand And Twenty Equity Incentive Plan [Member]
2020 Equity Incentive Plan [Member]
Represents Expected Cash Payment Payable.
Expected Cash Payment Payable
Expected Cash Payment Payable
Operating Leases, Rent Expense
Operating lease rental expenses
Operating Leases, Rent Expense, Total
Fully drawn amount
Fully Drawn Amount
Fully drawn amount.
Operating Income (Loss)
Loss from operations
Loss from operations
Equity and Term B Milestone [Member]
Equity and Term B Milestone [Member]
Entity Emerging Growth Company
At The Market Offering [Member]
Market Offering [Member]
Financial Instrument [Axis]
licensed products [Member]
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Prepaid expenses and other current assets
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Cancelled
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Options available for future grant
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Geographical [Axis]
Geographical [Axis]
Common stock $0.001 par value; 350,000,000 shares authorized, 215,950,561 shares issued and outstanding at March 31, 2022 and 350,000,000 shares authorized, 216,127,443 shares issued and outstanding at December 31, 2021
Common Stock, Value, Issued
Common Stock, Value, Issued, Ending Balance
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Total
Entity Address, State or Province
Interest Income (Expense), Net
Interest income (expense), net
Interest Income (Expense), Net, Total
Maximum amount of royalty payable.
Maximum Amount of Royalty Payable
Maximum royalty amount
Liabilities
Total liabilities
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Silicon Valley Bank [Member]
Silicon valley bank.
Represents Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones.
Description Of Option To Terminate The Agreement Upon Not Meeting Certain Milestones
Description Of option To terminate Agreement
Tcell receptor [Member]
T-cell receptor
Receivables, Net, Current
Receivables
Receivables, Net, Current, Total
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value
WatermillAndRobertWPostmaMember
Watermill And Robert W Postma [Member]
Watermill And Robert W Postma.
Class of Stock [Domain]
Class of Stock [Domain]
Percentage of sub licensing income, attributable to related party.
Percentage of Sub licensing Income Payable to Related Party
Portion of income payable to related party
License Agreement Terms [Member]
Aggregate Amount Potentially Reimburseable Amount.
Aggregate Amount Potentially Reimburseable Amount
Reimbursement of historical costs
Other Income and Expenses [Abstract]
Other income (expense):
Weighted average number of common shares outstanding used to compute basic and diluted net loss per share
Weighted Average Number of Shares Outstanding, Basic and Diluted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares
Debt Instrument Redemption Period Two Member
Debt Instrument, Redemption, Period Two [Member]
Banking and Thrift, Interest [Abstract]
Maximum amount of additional milestones payable.
Maximum Amount of Additional Milestones Payable
Expected additional milestones payable
Legal Entity [Axis]
Legal Entity [Axis]
Issuance and sale of common stock in public offering price per share.
Issuance And Sale of Common Stock In Public Offering Price Per Share
Issuance & sale of common stock in public offering price per share
General and Administrative Expense [Member]
General and Administrative Expense
General and Administrative [Member]
Represents Potential Benchmark Payments Payable.
Potential Benchmark Payments Payable
Potential Benchmark Payments Payable
Line of Credit Facility, Remaining Borrowing Capacity
Debt remaining borrowing capacity
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Options exercisable, at end of period
Common Stock, Call or Exercise Features
Exercise price
Debt Instrument, Redemption, Period [Domain]
Line of Credit Facility, Frequency of Payment and Payment Terms
Description of payment terms
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Significant Accounting Policies [Text Block]
Summary of Significant Accounting Policies
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
City Area Code
Deposits Assets, Noncurrent
Deposits
MA
MA [Member]
Boston, MA
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value
Annual base rent.
Annual Base Rent
Annual Base Rent
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Cancelled
Commitments and contingencies (Note 8)
Commitments and Contingencies
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share
Debt Instrument, Basis Spread on Variable Rate
Line of credit facility, interest rate
Scenario [Axis]
Consolidated Entities [Domain]
Debt Instrument, Redemption, Period [Axis]
Royalty Expense
Royalty fee
Debt instrument principal payments percentage.
Debt instrument Principal payments percentage
Debt instrument principal payments percentage
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents, and restricted cash, end of period
Cash and cash equivalents, and restricted cash, beginning of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Number of warrants issued
Related Party [Domain]
Related Party [Domain]
Income Statement [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net Cash Provided by (Used in) Investing Activities
Net cash used in investing activities
Debt Disclosure [Text Block]
Debt
Capital Expenditures Incurred but Not yet Paid
Amounts included in accrued expenses and accounts payable related to property and equipment
General and Administrative Expense
General and Administrative Expense, Total
General and administrative
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net, Ending Balance
Property, Plant and Equipment, Net, Beginning Balance
Property and equipment, net
Property, Plant and Equipment, Net, Total
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Issued, Total
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Cancelled
Cancelled
Restructuring and Related Cost, Number of Positions Eliminated
Operating Lease, Right-of-Use Asset
Right of use asset
Tenth Scheduled Payment Member
Tenth Scheduled Payment [Member]
Tenth Scheduled Payment.
Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.
Financing Arrangements Disclosure [Text Block]
Financings
Security Exchange Name
Statistical Measurement [Domain]
Range [Domain]
Term Loan Agreement [Member]
Term Loan Agreement [Member]
Accretion of term loan final payment.
Accretion Of Term Loan Final Payment
Accretion of term loan final payment
Net loss applicable to common stockholders
Net Income (Loss) Available to Common Stockholders, Basic
Net Income (Loss) Available to Common Stockholders, Basic, Total
Cash and Cash Equivalents, Fair Value Disclosure
Cash equivalents
Line of Credit Facility, Maximum Borrowing Capacity
Additonal tranche facility
Maximum borrowing capacity under the credit facility
Debt Disclosure [Abstract]
Document Period End Date
Income Statement Location [Axis]
Income Statement Location [Axis]
Accrued Liabilities, Current
Accrued expenses
Accrued Liabilities, Current, Total
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]
Stock-Based Compensation Expense on All Employee and Non-Employee Awards
Line of Credit Facility, Lender [Domain]
Warrants and Rights Outstanding, Term
Warrants fully vested upon issuance
Common stock issuance cost.
Common Stock Issuance Cost
Issuance of common stock, commissions and expenses
Warrant [Member]
Warrants
Payments due prior to the first marketing approval
Accruals Prior to First Marketing Approval
Payments due prior to the first marketing approval for TCR products.
Patent and technology license agreement.
Patent And Technology License Agreement [Member]
Type of Restructuring [Domain]
Eden Biocell.
Eden Biocell [Member]
Common Stock, Shares Authorized
Common stock, shares authorized
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Related Party [Axis]
Related Party [Axis]
Supplemental Cash Flow Information [Abstract]
Supplementary disclosure of cash flow information:
Class of Stock [Axis]
Class of Stock [Axis]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Antidilutive securities excluded from computation of earnings per share, amount
Schedule of Long-term Debt Instruments [Table]
Interest Expense, Debt
Interest expense
Interest Expense, Debt, Total
Vesting [Axis]
Debt Instrument, Maturity Date
Debt Instrument, maturity date
Represents Description Of First Benchmark Payable.
Description Of First Benchmark Payable
Description Of First Benchmark Payable
Interest Paid, Excluding Capitalized Interest, Operating Activities
Cash paid for interest
Initial borrowing zero milestones.
Initial Borrowing Zero Milestones [Member]
Initial Borrowing Zero Milestones [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Assets and Liabilities Measured at Fair Value on Recurring Basis
Entity Address, Address Line Two
Current Fiscal Year End Date
Net decrease in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Operating Lease, Cost
Operating lease cost
Share Subscription Agreement
Share Subscription Agreement [Member]
Non Vested Stock [Member]
Non Vested Stock [Member]
Unvested Stock
Equity Method Investment, Ownership Percentage
Equity interest in affilated entity
Maximum royalties amount payable
Maximum Royalties Amount Payable
Maximum royalties amount payable.
Assets [Abstract]
ASSETS
Employee Benefit and Share-based Payment Arrangement, Noncash
Employee Benefit and Share-based Payment Arrangement, Noncash, Total
Stock-based compensation
Warrants issued
Debt Conversion, Converted Instrument, Warrants or Options Issued
Organization
Business Description and Basis of Presentation [Text Block]
Business
Lessee, Operating Lease, Liability, to be Paid, Year One
2022
Accounts Payable, Current
Accounts payable
Accounts Payable, Current, Total
Debt Instrument, Name [Domain]
Schedule of Subsidiary or Equity Method Investee [Table]
Private Placement [Member]
Debt Instrument, Face Amount
Debt instrument, face amount
Common Stock, Par or Stated Value Per Share
Common stock, par value
Payment Type [Axis]
Public Offering [Member]
Public Offering [Member]
Public Offering [Member]
Shares, Outstanding
Balance (in shares)
Balance (in shares)
Additional Paid in Capital, Common Stock
Additional Paid in Capital, Common Stock, Ending Balance
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in capital
Payment Type [Domain]
Intrexon Corporation/Precigen [Member]
Intrexon Corporation
Operating Costs and Expenses [Abstract]
Operating expenses:
Document Type
Vesting [Domain]
Secured Debt
Secured Debt [Member]
Term B Tranche.
Term B Tranche [Member]
Term B Tranche [Member]
Assets, Current
Total current assets
Common Stock Options
Share-based Payment Arrangement, Option [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Securities Purchase Agreement.
Securities Purchase Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Outstanding, at end of period
Stock Options and Restricted Stock Awards
Stock Options and Restricted Stock Awards [Text Block]
Stock-Based Compensation
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Supplementary disclosure of noncash investing and financing activities
Earnings Per Share, Basic and Diluted
Basic and diluted net loss per share
Earnings Per Share, Basic and Diluted, Total
Line of Credit Facility, Interest Rate During Period
Interest rate
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Ending Balance
Beginning Balance
Payments to Fund Long-term Loans to Related Parties
Payments to Fund Long-term Loans to Related Parties
Restructuring and Related Cost, Expected Number of Positions Eliminated
Restructuring , expected number of positions eliminated
Common Stock, Shares, Outstanding
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding
Class of Warrant or Right [Domain]
Svb Warrants [Member].
Svb Warrants [Member]
SVB Warrants [Member]
Plan Name [Axis]
Plan Name [Axis]
Due date [Domain]
Eighth Scheduled Payment
Eighth Scheduled Payment.
Eight Scheduled Payment [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Cancelled
Line of Credit Facility, Current Borrowing Capacity
Initial borrowing
Initial term loan
Sale of Stock, Consideration Received on Transaction
Issuance of common stock in connection with a public offering, net
Sale of stock consideration received on transaction
Operating Expenses
Total operating expenses
Warrants member.
Warrants [Member]
Warrants [Member]
Lease, Cost
Lease, Cost, Total
Total lease cost
Financial Instruments [Domain]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Adjustment to additional paid in capital stock issuance costs
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Ending Balance
Beginning Balance
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash flows from operating activities:
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
Lessee, Operating Lease, Liability, Maturity
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrant exercise per share
Earnings Per Share [Abstract]
Maximum royalty amount
Maximum Royalty Amount
Maximum amount of royalty.
Lessee, Operating Lease, Liability, to be Paid, Year Two
2023
Net Income (Loss) Attributable to Parent
Net loss
Net loss
Operating Lease, Weighted Average Discount Rate, Percent
Weighted-average discount rate
Research and Development Expense [Member]
Research and Development Expense
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total
Stock options, granted
Document Fiscal Period Focus
Accounting Policies [Abstract]
Related party transaction expenses from transactions with related party advisory fees.
Related Party Transaction Expenses From Transactions With Related Party Advisory Fees
Warrants issued in term loan.
Warrants issued in term loan
Warrants issued in a term loan
Entity Address, Address Line One
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Ending Balance
Beginning Balance
Outstanding options issued
Stock option, outstanding
MD Anderson Agreement and Worldwide License [Member]
MD Anderson Agreement and Worldwide License.
Liabilities, Current
Total current liabilities
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]
Entity Address, Postal Zip Code
Debt Instrument, Periodic Payment
Debt instrument, periodic payment
Debt Instrument, Periodic Payment, Total
Title of Individual [Axis]
Title of Individual [Axis]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, Maximum
Fair Value Assumptions Risk Free Interest Rate Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Outstanding, at end of period
Lessee, Operating Lease, Liability, to be Paid
Total lease payments
Product and Service [Domain]
Warrants Disclosure [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Arrangements and Non-arrangement Transactions [Domain]
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Equity Option [Member]
Stock Option [Member]
Equity Components [Axis]
Equity Components [Axis]
License agreement commencement date.
License Agreement Commencement Date
Agreement commencement date
Proceeds from Issuance of Long-term Debt
Proceeds from long-term debt borrowing
Proceeds from Issuance of Long-term Debt, Total
Lease, Cost [Table Text Block]
Components of Lease Expense
Assets, Current [Abstract]
Current assets:
Tri Arm
Tri Arm [Member]
TriArm [Member]
Non Operating Income Expense Inducement Of Warrants.
Non Operating Income Expense Inducement Of Warrants
Non-cash inducement warrant expense
Entity Registrant Name
Postemployment Benefits, Period Expense
Accrued liability associated with force reduction
Amortization of Debt Issuance Costs
Amortization of financing costs
Debt instrument balance amount in the collateral account
Debt Instrument, Collateral Amount
Text Block [Abstract]
Prepayment premium percentage
Percentage of prepayment premium
Percentage of prepayment premium
Entity Interactive Data Current
Prime Rate [Member]
Prime Rate [Member]
Entity Address, City or Town
One Time Benchmark Payments [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Expected volatility, Minimum
Pocket expenses
Pocket Expenses
Pocket expenses.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Expected life in years
Fair Value Assumptions Expected Term1
Trading Symbol
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Net Cash Provided by (Used in) Investing Activities [Abstract]
Cash flows from investing activities:
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest and adjustments
Less: Imputed interest and adjustments
Local Phone Number
Before august six two thousand twenty two.
Before August Six Two Thousand Twenty Two [Member]
On or before August 6, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]
Weighted Average Contractual Term (Years)
Stockholders' Equity Attributable to Parent
Balance
Balance
Total stockholders' equity
Payments of Debt Issuance Costs
Debt issue costs paid
Debt issuance costs
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price
Obligations due under contract.
Obligations Due Under Contract
Obligations due under contract
Net proceeds from at the market stock offering.
Net Proceeds From At The Market Stock Offering
Issuance of common stock in connection with at the market offerings, net
Debt Instrument, Description of Variable Rate Basis
Debt instrument description of variable rate basis
Statistical Measurement [Axis]
Range [Axis]
Entity Small Business
Amount of Lessee Operating Lease Monthly Average Rental Payment .
Lessee Operating Lease Monthly Average Rental Payment
Operating Lease Monthly Rental Payment
Share Price
par value per share
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy [Domain]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Credit Facility [Axis]
Long-term debt
Long-term Debt, Excluding Current Maturities
Long-term debt
Variable Rate [Axis]
Share-based Payment Arrangement, Tranche Two [Member]
Milestone payments maximum amount.
Milestone Payments, Maximum Amount
Milestone maximum payment
Variable Rate [Domain]
Entity [Domain]
Entity [Domain]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Fair Value Adjustment of Warrants
Fair value of adjustment of warrants
Fair value of the warrants
Term B Milestone [Member]
Term B Milestone [Member]
Stock offered during period shares.
Stock Offered During Period Shares
Stock issued during period
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted
Sale of Stock [Domain]
Class Of Warrant Or Right Axis.
Class Of Warrant Or Right Axis [Axis]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Operating leases future minimum monthly payment due through year four.
Operating Leases Future Minimum Monthly Payment Due Through Year Four
Operating Leases Future Minimum Monthly Payment Due Through Year 2021
Land Subject to Ground Leases
Plan Name [Domain]
Plan Name [Domain]
Class of Stock [Line Items]
Class of Stock [Line Items]
ZiopLicenseAgreementWithTheNationalCancerInstituteMember
Ziop License Agreement With The National Cancer Institute [Member]
Ziop License Agreement With The National Cancer Institute [Member]
Lender Name [Axis]
Depreciation
Depreciation
Depreciation, Total
The University Of Texas M D Anderson Cancer Center And The Texas A And M University System
The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]
The University of Texas MD Anderson Cancer Center and The Texas A & M University System
Payment under license agreement
Payment Under License Agreement
Payment under license agreement.
Stock Issued During Period, Value, New Issues
Net Proceeds from Underwriting
Issuance of common stock in connection with at the market offering, net
Fees and Expenses, Related Party
Costs and Expenses, Related Party
Debt Instrument, Unamortized Discount
Debt Instrument, Unamortized Discount, Total
Unamortized discount on Term Loan Agreement
Amount due to related party, current
Due to Related Parties, Current
Due to Related Parties, Current, Total
Share-based Payment Arrangement, Noncash Expense
Share-based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Prepaid Expense and Other Assets, Current
Prepaid expenses and other current assets
Share-based Payment Arrangement, Option, Activity [Table Text Block]
Stock Option Activity under Stock Option Plan
Related Party Transactions [Abstract]
Long-term Debt, Gross
Total debt
Total debt
Aggregate potential benchmark payments.
Aggregate potential benchmark payments
Aggregate potential benchmark payments
MD Anderson License and the Research and Development Agreement.
MD Anderson License and the Research and Development Agreement [Member]
Vineti Inc.
Vineti Inc [Member]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
Fair Value Measurements
Long-term Debt, Current Maturities
Less: current portion of long-term debt
Long-term Debt, Current Maturities, Total
Current portion of long-term debt
Less: current portion of long-term debt
Two Thousand And Three Equity Incentive Plan
Two Thousand And Three Equity Incentive Plan [Member]
2003 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Options exercisable, at end of period
Net Cash Provided by (Used in) Financing Activities
Net cash provided by financing activities
Commitments and Contingencies Disclosure [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Vested
Debt Issuance Costs, Net
Issuance costs
Debt Issuance Costs, Net, Total
Assets
Total assets
Lessee, Operating Leases [Text Block]
Leases
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Exercise of employee stock options (in shares)
Exercised
Statement [Line Items]
Statement [Line Items]
Liabilities and Equity
Total liabilities and stockholders' equity
Document Quarterly Report
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Class of Warrant or Right [Axis]
Dividends
Dividends
Dividends, Total
Statement of Cash Flows [Abstract]
Term A Tranche [Member]
Term A Tranche [Member]
Term A Tranche [Member]
Additional Paid-in Capital [Member]
Additional Paid In Capital
Title of 12(b) Security
Eden Bio Cell
Eden Bio Cell [Member]
Debt instrument, initial maturity date
Debt Instrument, Maturity Date Range, Start
Commitments and Contingencies Disclosure [Table]
Commitments and Contingencies Disclosure [Table]
Commitments and Contingencies Disclosure [Table]
Debt Instrument [Line Items]
Represents Aggregate Benchmark Payments Payable.
Aggregate Benchmark Payments Payable
Aggregate Benchmark Payments Payable
Award Type [Domain]
Equity Award [Domain]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Hierarchy [Axis]
Collaborative Arrangement [Member]
Fair Value, Inputs, Level 1 [Member]
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Lessee, Operating Lease, Liability, to be Paid, Year Four
2025
Collaboration agreement with solasia pharma K.K.
Collaboration Agreement With Solasia Pharma KK [Member]
Restricted Stock [Member]
Restricted Stock
Unvested Restricted Stock
Agreement termination notice period.
Agreement Termination Notice Period
Agreement termination, notice period
Nonoperating Income (Expense)
Other expense, net
Other income (expense), net
Entity Current Reporting Status
Md Anderson Warrant [Member]
MD Anderson Warrant [Member]
MD Anderson Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, Minimum
Scenario [Domain]
Restructuring and Related Activities Disclosure [Text Block]
Restructuring
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted
Warrants and Rights Outstanding, Maturity Date
Warrant Expiry date
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2021 (excluding the six months ended June 30, 2021)
Proceeds from collateral account
Proceeds from Issuance of Debt
Agreement Type [Axis]
Debt Instrument Redemption Period Three Member
Debt Instrument, Redemption, Period Three [Member]
Income Statement Location [Domain]
Income Statement Location [Domain]
Share-based Payment Arrangement, Tranche One [Member]
Ziopharm [Member]
Ziopharm [Member]
Payment For Annual License Fees.
Payment For Annual License Fees
Annual Licensing fee paid
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Options exercisable, at end of period
Increase (Decrease) in Accrued Liabilities
Accrued expenses
Increase (Decrease) in Accrued Liabilities, Total
Restructuring and Related Costs [Table Text Block]
Schedule of Restructuring Costs
Minimum [Member]
Minimum
Royalties amount payable thereafter
Royalties Amount Payable thereafter
Royalties amount payable thereafter.
Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Security Deposit
Stock Issued During Period, Value, Stock Options Exercised
Exercise of employee stock options
Lease liability - non-current portion
Finance Lease, Liability, Noncurrent
Leases, Operating [Abstract]
Schedule of Debt [Table Text Block]
Schedule of Debt
Restructuring Cost and Reserve [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted
Equity milestone.
Equity Milestone [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Number of Warrants
Number of securities into which the class of warrant converted
New Warrants [Member]
Zero Milestone [Member]
Zero Milestone [Member]
Net Cash Provided by (Used in) Financing Activities [Abstract]
Cash flows from financing activities:
Debt Instrument [Axis]
Outside two thousand twelve plan [Member]
Outside Two Thousand Twelve Plan [Member]
Outside 2012 Plan
Silicon Valley Bank loan.
Silicon Valley Bank Loan [Member]
Silicon Valley Bank Loan [Member]
Entity Filer Category
Severance Costs
Severance costs
Total Severance Expense
Document Fiscal Year Focus
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Nonvested Share Activity [Table Text Block]
Summary of Unvested Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Ending Balance
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Accumulated deficit
Term loan [Member]
Term Loan [Member]
Term Loan [Member]
Debt instrument, extended maturity date
Debt Instrument, Maturity Date Range, End
The increase (decrease) during the period in the carrying value of right of use asset reported as assets.
Increase Decrease In Right Of Use Asset
Right of use asset
Fair Value Disclosures [Abstract]
Principal payment beginning date.
Principal Payment Beginning Date
Principal payment beginning date
Maximum [Member]
Maximum [Member]
Entity Central Index Key
Revenue from Contract with Customer, Including Assessed Tax
Collaboration revenue
Two Thousand And Twelve Equity Incentive Plan
Two Thousand And Twelve Equity Incentive Plan [Member]
2012 Equity Incentive Plan [Member]
Equity Method Investments and Joint Ventures [Abstract]
Non Vested Restricted Stock
Non Vested Restricted Stock [Member]
Unvested Restricted Common Stock
Non Vested Restricted Stock [Member]
Entity Tax Identification Number
Equity Component [Domain]
Equity Component [Domain]
Preferred Stock, Par or Stated Value Per Share
Preferred stock par value
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Proceeds from Issuance of Private Placement
Proceeds from private placement
Issuance costs in accounts payable and accrued expenses.
Issuance costs in accounts payable and accrued expenses
Issuance costs in accounts payable and accrued expenses
August seven two thousand twenty three to term loan maturity date.
August Seven Two Thousand Twenty Three To term Loan Maturity Date [Member]
Between August 7, 2023 and Term Loan Maturity Date [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Expected recognition period
Chief Executive Officer [Member]
Chief Executive Officer
Consolidated Entities [Axis]
Subsequent Events [Abstract]
Performance Based Payments Member [Member]
Proceeds from Issuance of Long-term Debt and Capital Securities, Net
Gross proceeds from debt
Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total
License [Member]
Statement [Table]
Statement [Table]
Operating Lease, Weighted Average Remaining Lease Term
Operating lease area.
Operating Lease Area
Entity File Number
Lessee Operating Lease Monthly Rental Payment.
Lessee Operating Lease Monthly Rental Payment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
License agreement with PGEN therapeutics.
License Agreement With PGEN Therapeutics [Member]
License Agreement with the National Cancer Institute [Member]
Increase (Decrease) in Other Noncurrent Assets
Other noncurrent assets
Retained Earnings [Member]
Accumulated Deficit
Two Thousand Twelve Stock Option Plan [Member]
Accounting Standards Update [Domain]
Accounting Standards Update [Axis]
Collaboration revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Agreement Type [Domain]
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
CAR Products [Member]
Liabilities, Current [Abstract]
Current liabilities:
Increase (Decrease) in Operating Assets [Abstract]
(Increase) decrease in:
Impact of COVID-19 Pandemic
Impact of COVID19 Pandemic [Policy Text Block]
Impact of COVID-19 Pandemic
Lease liability - current portion
Finance Lease, Liability, Current
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Operating leases expiration month and year.
Operating Leases Expiration Month and Year
Operating lease expiration month and year
Operating Lease, Liability
Lease obligation
Operating Lease, Liability, Total
Present value of lease payments
Common Stock [Member]
Common Stock
Post Marketing Approval [Member]
Incurred expenses
Other Accrued Liabilities
Cover [Abstract]
Credit Facility [Domain]
August seven two thousand twenty two to august six two thousand twenty three.
August Seven Two Thousand Twenty Two to August Six Two Thousand Twenty Three [Member]
Between August 7, 2022 and August 6, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Ending Balance
Beginning Balance
Statement of Stockholders' Equity [Abstract]
Common stock
Common Stock, Shares Subscribed but Unissued
First benchmark payment
Initial Benchmark Payment Due
The first benchmark payment due upon the initiation of the Company's first sponsored phase.
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Restricted stock awards (in shares)
Share-based Payment Arrangement [Abstract]
Houston Texas [Member]
Houston Texas [Member]
Houston, TX
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited
Cancelled restricted common stock (in shares)
Document Transition Report
Additional number of warrants issued.
Additional Number Of Warrants Issued
Additional number warrants issued
Proceeds from Stock Options Exercised
Proceeds from exercise of stock options
Employee Severance [Member]
Employee Severance [Member]
Percentage of final payment due
Percentage Of Final Payment Due
Percentage of final payment due
Research and Development Expense
Research and development
Research and Development Expense, Total
Research and development expense
Schedule of Restructuring and Related Costs [Table]
The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.
Increase Decrease In Lease Liabilities
Lease liabilities
Commitments and Contingencies Disclosure [Line Items]
Commitments and Contingencies Disclosure [Line Items]
Accrued Payments
Sublease term commenced end date amendment.
Sublease Term Commenced End Date Amendment
Sublease term amendment
Statement of Financial Position [Abstract]
Subsidiary or Equity Method Investee [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Fair Value Assumptions Expected Dividend Rate
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Vested
Vested
Debt Instrument Redemption Period One
Debt Instrument, Redemption, Period One [Member]
Debt Instrument outstanding principal including accrued and unpaid interest
Line of Credit Facility, Maximum Amount Outstanding During Period
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' equity:
Minimum sales revenue on which benchmark payments payable
Minimum Sales Revenue On Which Benchmark Payments Payable
Minimum sales revenue on which benchmark payments payable.
Cash proceeds from sale of equity
Proceeds from Issuance or Sale of Equity
Proceeds from Issuance or Sale of Equity, Total
Interest expense amortized date.
Interest Expense Amortized Date
Interest expense amortized date
Due date [Axis]
Change in fair value
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Lessee operating lease liability payments due after year four.
Lessee Operating Lease Liability Payments Due After Year Four
Thereafter
Equity Method Investments and Joint Ventures Disclosure [Text Block]
Joint Venture
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised
Exercise price of stock options
Increase (Decrease) in Operating Capital [Abstract]
Change in operating assets and liabilities:
Lessee, Operating Lease, Liability, to be Paid, Year Three
2024
Entity Common Stock, Shares Outstanding
Common Stock, Capital Shares Reserved for Future Issuance
Common stock reserved for future issuance
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Award Type [Axis]
Award Type [Axis]
Entity Shell Company
Restructuring and Related Activities [Abstract]
Liabilities and Equity [Abstract]
LIABILITIES AND STOCKHOLDERS' EQUITY
Warrants expiration date
Warrants Expiration Date
Warrants Expiration Date
Black-Scholes Model [Member].
Black Scholes Model [Member]
Black-Scholes Model [Member]
Entity Incorporation, State or Country Code
Earnings Per Share [Text Block]
Net Loss per Share
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares
Amendment Flag
Schedule of Stock by Class [Table]
Schedule of Stock by Class [Table]
Product and Service [Axis]
Other Nonoperating Income (Expense)
Other income (expense), net
Other Nonoperating Income (Expense), Total
Cash and Cash Equivalents, at Carrying Value
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash balance
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Pronouncements
Title of Individual [Domain]
Relationship to Entity [Domain]
Placement agent fees and other related expenses.
Placement Agent Fees And Other Related Expenses
Placement agent fees and other expenses
Maximum Sales Revenue On Which Benchmark Payments Payable
Maximum Sales Revenue On Which Benchmark Payments Payable
CRADA Agreement
CRADA Agreement [Member]
Fair Value, Recurring [Member]
Fair Value, Measurements, Recurring
Subsequent Events [Text Block]
Subsequent Events
The entire disclosure pertaining to the warrant.
Warrant [Text Block]
Warrant
Class Of Warrant Or Right.
Class Of Warrant Or Right Domain [Domain]
License Expense
Amount of expense related to License payments.
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Other Assets, Noncurrent
Other non-current assets
Other Assets, Noncurrent, Total
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Type of Arrangement and Non-arrangement Transactions [Axis]
Geographical [Domain]
Geographical [Domain]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Options exercisable, at end of period
Prepaid Expenses and Other Current Assets [Member]
Prepaid Expenses and Other Current Assets
Sale of Stock [Axis]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Unrecognized compensation costs related to unvested restricted stock outstanding
Increase (Decrease) in Receivables
Increase (Decrease) in Receivables, Total
Receivables